MSCI (MSCI) Set to Release Quarterly Earnings on Tuesday

MSCI (NYSE:MSCI) is expected to release its Q3 2026 results before the market opens on Tuesday, October 20th. Analysts expect the company to announce earnings of $5.02 per share and revenue of $887.44 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 20, 2026 at 11:00 AM ET.

MSCI (NYSE:MSCI) last posted its quarterly earnings results on Tuesday, July 21st. The technology company reported $4.94 earnings per share for the quarter, missing the consensus estimate of $4.99 by ($0.05). MSCI had a negative return on equity of 55.19% and a net margin of 40.74%. The business had revenue of $867.00 million during the quarter, compared to analysts’ expectations of $870.71 million. During the same period in the prior year, the business posted $4.17 earnings per share. The business’s quarterly revenue was up 12.2% on a year-over-year basis. On average, analysts expect MSCI to post $19.55 EPS for the current fiscal year and $22.33 EPS for the next fiscal year.

MSCI Trading Down 1.3%

MSCI stock opened at $567.85 on Friday. The company has a 50-day moving average price of $558.93 and a 200 day moving average price of $575.34. MSCI has a 12-month low of $501.08 and a 12-month high of $644.77. The stock has a market cap of $41.28 billion, a P/E ratio of 31.06, a PEG ratio of 2.16 and a beta of 1.24.

MSCI Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were paid a dividend of $2.05 per share. The ex-dividend date was Friday, August 14th. This represents a $8.20 dividend on an annualized basis and a yield of 1.4%. MSCI’s dividend payout ratio is 44.86%.

Wall Street Analysts Forecast Growth

Several research firms have commented on MSCI. Bank of America boosted their price target on shares of MSCI from $715.00 to $730.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Wells Fargo & Company cut their price target on MSCI from $690.00 to $685.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 29th. Raymond James Financial lifted their price target on MSCI from $730.00 to $760.00 and gave the stock a “strong-buy” rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. lowered their price objective on MSCI from $700.00 to $685.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Jefferies Financial Group began coverage on MSCI in a research report on Friday, July 17th. They set a “buy” rating and a $760.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and eleven have given a Buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $701.17.

Insider Activity at MSCI

In other news, CFO Andrew Wiechmann sold 450 shares of the business’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $570.00, for a total value of $256,500.00. Following the completion of the sale, the chief financial officer directly owned 21,644 shares of the company’s stock, valued at approximately $12,337,080. The trade was a 2.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.76% of the company’s stock.

Key Stories Impacting MSCI

Here are the key news stories impacting MSCI this week:

• Positive Sentiment: MSCI’s upcoming third-quarter results are expected to benefit from strong demand for indexes, ETF inflows and growth in private-capital products. Analysts at RBC anticipate a modest earnings beat, offering a potential near-term catalyst. MSCI earnings expectations
• Positive Sentiment: MSCI launched a consultation to move Indonesia’s indexes from emerging-market to standalone status, with a final decision expected by June 2027. Although disruptive for Indonesian markets, the process reinforces MSCI’s role as a key global benchmark provider and may increase attention to its index-governance services. MSCI Indonesia reclassification consultation
• Neutral Sentiment: MSCI is also consulting on new index-eligibility rules that could eventually remove Strategy, formerly MicroStrategy, from some indexes. Existing constituents reportedly must fail eligibility screens across two consecutive annual filing periods, so the financial impact is not immediate. Strategy index eligibility proposal
• Neutral Sentiment: MSCI froze its Turkey indexes while market-access concerns remain under review. The action demonstrates stricter methodology enforcement but could create uncertainty for index-linked products and affected clients. MSCI Turkey index freeze
• Negative Sentiment: The Indonesia proposal has triggered a sharp sell-off in Indonesian equities and raised concerns about foreign outflows. The resulting criticism and political scrutiny may increase uncertainty around MSCI’s emerging-market franchise, even though the decision is still under consultation. MSCI Indonesia downgrade warning
• Negative Sentiment: Morgan Stanley lowered its MSCI price target from $700 to $662 while maintaining an Overweight rating. The cut reflects more cautious valuation expectations ahead of earnings, despite continued analyst support. MSCI price target reduction

MSCI Company Profile

MSCI Inc is a global provider of investment decision-support tools and services for institutional investors, asset managers, banks, wealth managers and other financial professionals. The company is best known for its equity, fixed-income and multi-asset-class indexes, which are used as benchmarks and as the basis for investment products such as exchange-traded funds and other index-linked strategies.

In addition to indexes, MSCI provides portfolio analytics, risk-management and performance-measurement tools designed to help clients evaluate exposures, construct portfolios and manage investment risks.